Reliance on invasive liver biopsy endpoints is a major limiting factor in new therapeutic development for metabolic dysfunction-associated steatohepatitis (MASH). While liver fat accumulation is considered a driver of early disease, liver fat reduction is not recognized as a surrogate endpoint by health authorities. He...
N. Verweij, G. Hindy, Q. Nguyen et al.· medRxiv· 0 citations
Altered energy metabolism is a shared driver across cardiometabolic diseases—the leading cause of death globally1. Energy metabolism varies between individuals and is partly heritable2, 3, 4, 5, 6, 7, 8–9. Here, to investigate the genetic basis of energy metabolism, we perform an exome-sequencing analysis of 1,032,116...
G. Hindy, Rene C. Adam, Olukayode A. Sosina et al.· Nature· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.